| IVZ |
Report |
Adjusted diluted EPS |
BEAT |
pred ~$0.72 vs. cons $0.67 |
MEDIUM |
| IVZ |
Report |
Net long-term organic inflows (Q2) |
BEAT |
pred ~$36B vs. cons $27B |
MEDIUM |
| IVZ |
Report |
Net revenue yield (bps) |
MISS |
pred ~22.5bps vs. cons 22.8bps |
MEDIUM |
| IVZ |
Guide |
FY2026 operating expense guidance |
LOWER |
guide ~$3.35B vs. cons $3.29B (FY2026) |
MEDIUM |
| IVZ |
Guide |
Total payout ratio (dividends+buybacks) |
BETTER |
guide ~60% vs. cons ~57% (FY2026) |
MEDIUM |
| IVZ |
Guide |
Net revenue yield trajectory (2H26 outlook) |
LOWER |
guide ~22.5bps vs. cons 22.8bps (2H2026) |
MEDIUM |
| IVZ |
Return |
Day-1 residual (stock − beta × S&P 500) |
-2.0% |
— |
MEDIUM |
| IVZ |
Return |
5-day cumulative residual |
-3.2% (FADE) |
Stock rallied ~16% in the month into the print and sits near its average sell-side target with beat-odds already priced in (Zacks flagged elevated beat probability); the mechanical QQQ AUM step-up means headline EPS/revenue growth surprises little on a like-for-like basis, while net revenue yield continues to erode on ETF/China mix shift and the FY26 expense guide likely creeps up from $3.275B given higher AUM-linked comp — none of which meaningfully raises out-year (2027) estimate revisions. With valuation already stretched after an ~86% 12-month run, the setup favors profit-taking/de-rating over the following days rather than continued follow-through, even if the print itself is a modest EPS beat. |
MEDIUM |